Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: A retrospective analysis

Leukemia Research

Volumn 38, Issue 12, 2014, Pages 1446-1450

  Merchionne, Francesca ^a   Quintana, Giovanni ^a   Gaudio, Francesco ^b   Minoia, Carla ^c   Specchia, Giorgina ^b   Guarini, Attilio ^c   Quarta, Giovanni ^a   Pavone, Vincenzo ^d   Melpignano, Angela ^a  

^a Division of Medical Oncology   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d Foundation Hospital Cardinal G Panico   (Italy)

Author keywords

Bendamustine; DLBCL; Rituximab; Salvage therapy

Indexed keywords

BENDAMUSTINE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RASH; REFRACTORY ANEMIA; SALVAGE THERAPY; THROMBOCYTOPENIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84916195853     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.10.001     Document Type: Article

References (24)

1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
2. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Tmeny M., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
3. Rummel M.J., Al-Batran S.E., Kim S.Z., Welslau M., Hecker R., Kofahl-Krauser D., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
4. Robinson K.S., Williams M.E., van der Jagt R.H., Cohen P., Herst J.A., Tulpule A., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
5. Rummel M.J., Niederle N., Maschmeyer G., Banat G.A., von Grunhagen U., Losem C., et al. Study group indolent lymphomas (StiL) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013, 381:1203-1210.
6. Flinn I.W., van der Jagt R., Kahl B.S., Wood P., Hawkins T.E., Macdonald D., et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014, 123:2944-2952.
7. Weidmann E., Kim S.-Z., Rost A., Schuppert H., Seipelt J., Hoelzer D., et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13:1285-1289.
8. Ogura M., Ando K., Taniwaki M., Watanabe T., Uchida T., Ohmachi, et al. Japanese Bendamustine Lymphoma Study Group. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Cancer Sci 2011, 102:1687-1692.
9. Walter E., Schmitt T., Dietrich S., Ho A., Witzens-Harigh M. Rituximab and bendamustine in patients with diffuse large cell CD20+B-cell lymphoma not eligible for a CHOP like chemotherapy. Leuk Lymphoma 2012, 53:2290-2292.
10. Ohmachi K., Niitsu N., Uchida T., Kim S.J., Ando K., Takahashi N., et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013, 31:2103-2109.
11. Vacirca J.L., Acs P.I., Tabbara I.A., Rosen P.J., Lee P., Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 2014, 93:403-409.
12. Weidmann E., Neumann A., Fauth F., Atmaca A., Al-Batran S.E., Pauligk C., et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011, 22:1839-1844.
13. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
14. El Gnaoui T., Dupuis J., Belhadj K., Jais J.P., Rahmouni A., Copie-Bergman C., et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007, 18:1363-1368.
15. Mounier N., El Gnaoui T., Tilly H., Canioni D., Sebban C., Casasnovas R.O., et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013, 98:1726-1731.
16. Witzig T.E., Vose J.M., Zinzani P.L., Reeder C.B., Buckstein R., Polikoff J.A., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
17. Witzig T.E., Reeder C.B., LaPlant B.R., Gupta M., Johnston P.B., Micallef I.N., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25:341-347.
18. Witzens-Harig M., Memmer M.L., Dreyling M., Hess G. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial. BMC Cancer 2013, 13:308.
19. Kiewe P., Thiel E. Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma. Ann Hematol 2011, 90:109-110.
20. Ruan J., Martin P., Furman R.R., Lee S.M., Keung K., Vose J.M., et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29:690-697.
21. Elstrom R.L., Andemariam B., Martin P., Ruan J., Shore T.B., Coleman M., et al. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2012, 53:1469-1473.
22. Crump M., Coiffier B., Jacobsen E.D., Sun L., Ricker J.L., Xie H., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19:964-969.
23. Robertson M.J., Kahl B.S., Vose J.M., de Vos S., Laughlin M., Flynn P.J., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:1741-1746.
24. Stopeck A.T., Unger J.M., Rimsza L.M., Bellamy W.T., Iannone M., Persky D.O., et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma 2009, 50:728-735.